T-Cell Engager Called Major Breakthrough In Children With B-Cell ALL

The T-cell engager blinatumomab (Blincyto, Amgen) was characterized as a “major breakthrough” in ...

DECEMBER 20, 2024

Researchers Identify Genes Linked to Relapse in Standard-Risk B-Cell Acute Lymphoblastic Leukemia

Researchers have identified genetic variations that influence relapse risk in children with standard-risk B-cell ...

AUGUST 26, 2024

Measurable Residual Disease Testing in the Community Oncology Setting

In the game of chess, anticipating the correct response to each of your opponent’s moves on the board can ...

FEBRUARY 7, 2024

Anti-CD19 CAR T-Cell Therapy Shows Efficacy in R/R B-Cell ALL in Adults

A single infusion of anti-CD19 chimeric antigen receptor T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) ...

SEPTEMBER 22, 2021

Report from ASH 2019: Large Benefit With Blinatumomab in Trial of Younger B-ALL Patients

ORLANDO, FLA.—In children, adolescents and young adults with B-cell acute lymphoblastic leukemia who have ...

DECEMBER 23, 2019

ALL Has Potential to Relapse After CAR T-Cell Therapy

B-cell acute lymphoblastic leukemia can recur when leukemic cells become resistant to chimeric antigen receptor ...

OCTOBER 26, 2018

CAR T-Cell Benefit in ALL Appears Greater With Low Disease Burden

Washington—Among patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), the ...

MAY 10, 2017